1.
Clinical Study of the Expression of Tissue Factor and Urokinase Plasminogen Activator Receptor in Breast Cancer
组织因子、尿激酶型纤溶酶原激活剂受体在乳腺癌中的表达
2.
Comparison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test
重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较
3.
Study on Recombinant Nonglycosylated Urokinase-type Plasminogen Activator;
重组非糖基化尿激酶型纤溶酶原激活剂的研究
4.
Clinical Significance of Measurement of Plasma Urokinase Type Plasminogen Activator and its Receptor in Cancer Patients
癌症患者尿激酶型纤溶酶原激活物及其受体检测的临床意义
5.
The Relationship between the Expression of Yrokinase-type Plasminogen Activator Receptor,and the Infiltration and Metastasis of Gastric Cancer
尿激酶型纤溶酶原激活物受体表达与胃癌浸润和转移过程的关系
6.
Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis
骨关节炎滑膜中尿激酶型纤溶酶原激活物及其受体蛋白的表达
7.
Expression and Regulation of Urokinase-type Plasminogen Activator in Supraglottic Laryngeal Cancer;
尿激酶型纤溶酶原激活剂在声门上型喉癌中的表达及调节机制
8.
Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in multiple myeloma patients;
多发性骨髓瘤患者血浆尿激酶型纤溶酶原激活物及其可溶性受体的检测
9.
Significance of Urokinase-type Plasminogen Activator and Urokinase-type Plasminogen Activator Receptor in Synovial Fluid of Patients with Temporomandibular Disorders;
颞下颌关节紊乱病关节液中尿激酶型纤溶酶原激活物及其受体的检测
10.
The Relationship of LN-R and uPA in Invasive Ductal Breast Cancer
层粘连蛋白受体、尿激酶型纤溶酶原激活物在乳腺浸润性导管癌中的表达及其相关性
11.
Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;
慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
12.
Epidermal growth factor differently modulate activity of urokinase plasminogen activator and plasminogen ac-tivator inhibitor-1 in oral squamous cell carcinoma and metastasis carcinoma cell lines
外源性表皮生长因子对口腔鳞癌细胞系尿激酶型纤溶酶原激活剂及其抑制剂活性的影响
13.
Comparative study on intravenous rt-PA and uroninase thrombolytic strategy for acute myocardial infarction
重组组织型纤溶酶原激活剂与尿激酶静脉内溶栓治疗急性心肌梗死的比较研究
14.
Treatment of Experimental Hepatic Fibrosis by Combination of Urokinase-type Plasminogen Activator and Hepatocyte Growth Factor Gene Delivery;
尿激酶型纤溶酶原激活剂和肝细胞生长因子联合基因治疗实验性肝纤维化
15.
Effect of Chinese Hebal Compound of Different Treating Principles on uPA of Cholestasis-induced Liver Fibrosis Rat
不同治则中药复方对胆汁淤积性肝纤维化大鼠尿激酶型纤溶酶原激活剂的影响
16.
Dynamic changes and its significance of urokinase-plasminogen activator during forming progress of cholestatic liver fibrosis in rats
尿激酶型纤溶酶原激活剂在大鼠胆汁淤积性肝纤维化形成过程中的动态变化及其意义
17.
Effects of Tang Maiping on Plasminogen Activeator Inhibior in Blood Vessel of Type 2 Diabetic Rats
糖脉平对2型糖尿病大鼠血管纤溶酶原激活抑制剂表达的影响
18.
Cloning and Expression of Urokinase Type Plasminogen Activator cDNA
尿激酶型纤溶酶原激活因子cDNA的克隆与原核表达